Notably, the inhibition of DRP1 via a dominant-negative mutant or a pharmacologic inhibitor midivi-1 could block mitochondrial fragmentation and protect kidneys against ischemia or cisplatin nephrotoxic AKI [6, 10]. Here, DNM1L is linked to acute kidney injury.